Study authors reviewed the evidence on the effectiveness of low-dose aspirin in the primary prevention of cardiovascular disease in systemic autoimmune rheumatic diseases.
Researchers described patients with autoimmune inflammatory rheumatic diseases with COVID-19 and the risk factors associated with hospitalization related to COVID-19.
Researchers evaluated the possibility of SARS-CoV-2 infection accelerating the onset of an autoimmune rheumatic disease.
Researchers evaluated the prevalence of hospital-diagnosed COVID-19 in chronic inflammatory and autoimmune rheumatic diseases.
In this Q&A, Maximilian Konig, MD, provides further insight into the overall effect of COVID-19 on patients with autoimmune diseases.
Study leads Shilpa Venkatachalam, PhD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.
Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in combination with methotrexate (MTX) was shown to be successful and well-tolerated in patients with chronic inflammatory/autoimmune diseases.
Researchers examined the association between maternal autoimmune disorders and the risk for Kawasaki disease in offspring.
Patients with chronic hepatitis C (HCV) achieving sustained virologic response to pegylated interferon plus ribavirin therapy did not exhibit an effect on the incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis.
Researchers investigated whether the influenza vaccine was effective in preventing respiratory morbidity, mortality, and all-cause mortality in patients with autoimmune rheumatic diseases.
